Clinical trials: Cancer Patients and Physical Activity
Metastatic Castration-resistant Prostate Cancer
A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer
The overall objective of this Phase 1 study is to evaluate the safety, PK, and anti-tumor activity of 12 weeks of daily oral dosing with HP518 after selecting the RP2D of HP518 based on assessments of multiple dose escalation in…
- Trial name
- NCT05252364
- Testing
- HP518 - Dose Escalation, HP518 - Dose expansion
- Where
- 5 sites in Australia
- Volunteers
- 22 people
- Sponsor
- Hinova Pharmaceuticals Aus Pty Ltd
Advanced Malignant Tumors
A Study of AK130 in Patients With Advanced Malignant Tumors
A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AK130 (TIGIT/TGF-β bifunctional fusion protein) in patients with advanced malignant…
- Trial name
- NCT05653284
- Testing
- AK130
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Akeso
Solid Tumor, Adult
Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors
This is a phase I/IIa, two-part, open-label study to characterize the safety, tolerability, pharmacodynamics, and antitumor activity of ICT01 in combination with LDSC IL-2 in patients with advanced-stage solid tumors.
- Trial name
- EVICTION-2 (NCT05307874)
- Testing
- ICT01, Proleukin Injectable Product, Pembrolizumab injection
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 56 people
- Sponsor
- ImCheck Therapeutics, an Ipsen company
Locally Advanced/Metastatic Solid Tumors
First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study
First-in-Human, Phase I, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of FL115 in patients with advanced solid tumors who have…
- Trial name
- NCT06130722
- Testing
- FL115
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Suzhou Forlong Biotechnology Co., Ltd
Advanced Cancer, Metastatic Cancer
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies
- Trial name
- NCT04648202
- Testing
- FS120
- Where
- 9 sites in United States, Spain
- Volunteers
- 82 people
- Sponsor
- invoX Pharma Limited
Neoplasms
Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor Activity
Open label Phase I study of Regorafenib to evaluate cardiovascular safety, tolerability and anti-tumor activity in patients with advanced solid tumors
- Trial name
- NCT01339104
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- 6 sites in United States
- Volunteers
- 53 people
- Sponsor
- Bayer
Relapsed or Refractory Multiple Myeloma
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-06 and to characterize the safety and tolerability of EMB-06 at the RP2Ds.
- Trial name
- NCT04735575
- Testing
- EMB-06
- Where
- 10 sites in Australia, China
- Volunteers
- 40 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Melanoma
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma
The clinical objective of this clinical trial is to examine the clinical activity in terms of tumor response and time to treatment failure of the immunotherapeutic product GSK2132231A when given to patients with unresectable and…
- Trial name
- NCT00896480
- Testing
- Immunotherapeutic GSK2132231A
- Where
- 8 sites in Belgium, France
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Melanoma
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients
A Phase 1b study to evaluate the safety and tolerability of MB097 given in combination with pembrolizumab in patients with melanoma who demonstrate primary resistance to anti-PD1 therapy.
- Trial name
- MELODY-1 (NCT06540391)
- Testing
- MB097, Pembrolizumab, Vancomycin
- Where
- 19 sites in France, Italy and 2 more
- Volunteers
- 41 people
- Sponsor
- Microbiotica Ltd
Breast Cancer
Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy
The study is a prospective, multicenter, observational study to evaluate PRO and physical activity using smartphone-based application and wearable device in Japanese patients with HR+/HER2- advanced breast cancer (ABC).
- Trial name
- JBCRG-26 (NCT04736576)
- Testing
- Wearable device
- Where
- 20 sites in Japan
- Volunteers
- 99 people
- Sponsor
- Pfizer
Liver Neoplasms, Unresectable Hepatocellular Carcinoma
An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer
The study will consist of two parts. In Part 1 the study will start enrolling 38 patients and then further 25 patients up to a total of 63 eligible patients.
- Trial name
- NCT00247676
- Testing
- Sunitinib (SU011248)
- Where
- 8 sites in France, South Korea and 1 more
- Volunteers
- 37 people
- Sponsor
- Pfizer
NSCLC, SCLC
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study.
- Conditions
- NSCLC, SCLC, CRPC, ESCC
- Trial name
- NCT04686682
- Testing
- JAB-8263
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Metastatic Cancer, Solid Tumor
Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
This was the first study to test Sym023 in humans. The primary purpose of this study was to see if Sym023 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas…
- Conditions
- Metastatic Cancer, Solid Tumor, Lymphoma
- Trial name
- NCT03489343
- Testing
- Sym023
- Where
- 4 sites in United States, Canada
- Volunteers
- 24 people
- Sponsor
- Symphogen A/S
Solid Tumors (Phase 1), Mesothelioma
Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if drug AROG4-01 is safe in patients with solid tumors who have no available treatment alternative. Different doses will be tested in order to identify the most suitable one.
- Conditions
- Solid Tumors (Phase 1), Mesothelioma, Colorectal Carcinoma, Ovarian Cancer
- Trial name
- AROG4-01-01 (NCT06652529)
- Testing
- AROG4-01
- Volunteers
- 35 people
- Sponsor
- Aromics Therapeutics
B-cell Acute Lymphoblastic Leukemia
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL).
- Trial name
- NCT04150497
- Testing
- UCART22, CLLS52
- Where
- 19 sites in United States, France
- Volunteers
- 52 people
- Sponsor
- Cellectis S.A.
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
To determine the anti-tumour activity and biological effects of cediranib (AZD2171) at a dose of 45mg, primarily in Gastrointestinal Stromal Tumour (GIST) patients who are resistant to imatinib mesylate (current standard therapy)…
- Trial name
- NCT00385203
- Testing
- AZD2171
- Where
- 2 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- AstraZeneca
Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
This trial is a multicenter, open-label, single-arm, dose-escalation and dose-expansion clinical trial. The dose was increased according to the "3 + 3" rule.
- Trial name
- NCT07035379
- Testing
- TRS005, Cyclophosphamide, Doxorubicin
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
Advanced Cancer, Metastatic Cancer
FS222 First in Human Study in Patients With Advanced Malignancies
This study will be conducted in adult participants diagnosed with advanced tumours to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS222.
- Trial name
- NCT04740424
- Testing
- FS222
- Where
- 21 sites in Australia, Georgia and 5 more
- Volunteers
- 260 people
- Sponsor
- invoX Pharma Limited
EGFR Mutant Advanced Non-small Cell Lung Cancer
A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
This study is a Phase I/II open-label, multi-center study to evaluate the safety, tolerability, PK, and an anti-tumor activity of JIN-A02, a 4th generation EGFR-TKI agent for oral administration, in EGFR mutant-positive, advanced…
- Trial name
- NCT05394831
- Testing
- JIN-A02
- Where
- 10 sites in United States, South Korea and 1 more
- Volunteers
- 150 people
- Sponsor
- J Ints Bio
Advanced Solid Tumors, Pancreatic Cancer
Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
This study is an open label, two-part, First in Human (FIH) Phase 1/2 dose-finding study designed to determine the safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and proof-of-concept (POC) of OMO-103 in…
- Conditions
- Advanced Solid Tumors, Pancreatic Cancer, CRC
- Trial name
- MYCure (NCT04808362)
- Testing
- OMO-103
- Where
- 3 sites in Spain
- Volunteers
- 22 people
- Sponsor
- Peptomyc S.L.